Strike Back Overview

Welcome to Strike Back Envenomation Education

Our mission is to provide educational information and resources to help you prepare the best treatment possible at every stage of a pit viper envenomation.

Prepare. Protect. Perform.

How to Treat a Snakebite

Use the interactive guide with step-by-step instructions on how to treat a snakebite.

LAUNCH ALGORITHM

Review resources on the treatment algorithm for the management of crotaline snakebites.

GET STARTED

Achieving Control

Learn about resolving all 3 critical components of pit viper envenomation in order to achieve initial control.

LEARN MORE

Myths About Treatment

Find out which common treatment myths to avoid when treating North American pit viper envenomation.

REVIEW MYTHS

Snakes in Your State

Learn which snakes you may encounter in your area by visiting our interactive map.

View map

About Pit Viper Envenomation

Learn about the impact North American pit viper envenomation can have on your patients.

LEARN MORE

Did You Know?

98% of venomous snakebites in the United States are from the North American pit viper, including copperheads, cottonmouths, and rattlesnakes.¹ Make sure you're prepared with treatment that covers this entire range.

Understand the Risk for North American Pit Viper Envenomation and Know How to Act Quickly

Since the consequences of pit viper envenomation may be severe, it’s important to understand the impact of venom on the patient and follow an established treatment protocol.

According to the Department of Wildlife Ecology and Conservation at the University of Florida, approximately 8,000 venomous snakebites occur each year in the United States.²

Between 2000 and 2007, the number of pit viper bites reported to poison control centers has increased 243%.³

The increase may partially reflect an increased use of US poison control centers

Strike Back Envenomation Education will help you prepare for every stage of a snakebite envenomation.

Review information about North American pit viper envenomation and its impact on patients.

Learn the Basics >

References:

1. Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report. Clin Toxicol. 2017;55(10):1072-1252. 2. Frequently Asked Questions. Department of Wildlife Ecology and Conservation website. Ufwildlife.ifas.ufl.edu/venomous_snake_faqs.shtml. Accessed May 23, 2018. 3. Spiller HA, Bosse GM, Ryan ML. Use of antivenom for snakebites reported to United States poison centers. Am J Emerg Med. 2010;28(7):780-785.

Algorithm

Review the expert consensus for managing pit viper snakebites.

Dosing + Administration

Learn how to dose CroFab® to gain and continue control of pit viper envenomation.

Patient Experiences

Watch testimonials and review case studies to learn from patient experiences.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer CroFab® to patients with a known history of hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.

WARNINGS AND PRECAUTIONS

Coagulopathy: In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.

Hypersensitivity Reactions: Severe hypersensitivity reactions may occur with CroFab®. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia).

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur.

Please see full Prescribing Information.

INDICATION

CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.

BTG and the BTG roundel logo are registered trademarks of BTG International Ltd.
CroFab ^® is a registered trademark of BTG International Inc.
TIME IS TISSUE^® is a trademark of Protherics Medicines Development Ltd., a BTG International group company. BTG Specialty Solutions Center^™ is a trademark of BTG International Ltd. SnakeBite911 and the snakehead logo are trademarks of Protherics UK Ltd. Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. ‭Google Play and the Google Play logo are trademarks of Google Inc.

© 2020 BTG International Inc. All rights reserved.
US-CRF-1900219 October 2019

To report suspected adverse reactions, contact BTG at
1-877-377-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

BTG Specialty Solutions Center^TM

	1-844-293-0007 (Voice)
	1-877-626-9910 (Fax)

24-hour Medical Information:

1-877-377-3784